Gritstone Oncology to Webcast Presentations from Two Upcoming Investor Conferences in September

Rhea-AI Summary

Gritstone Oncology (Nasdaq: GRTS), a biotechnology firm focused on cancer immunotherapy, will have its CEO Andrew Allen presenting at two investor conferences this September. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 a.m. ET and the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 9:20 a.m. ET. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event.

Gritstone is developing next-gen cancer treatments through its innovative machine learning platform and neoantigen therapies.

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a webcasted company overview at two upcoming investor conferences in September.

• H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 a.m. ET
  
  
• Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 9:20 a.m. ET

A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone Oncology
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGE^TM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhouselsa.com

FAQ

When will Gritstone Oncology present at investor conferences in September 2020?

Gritstone Oncology will present at the H.C. Wainwright Global Investment Conference on September 14, 2020, at 10:30 a.m. ET, and at the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 9:20 a.m. ET.

How can I access the Gritstone Oncology conference presentations?

You can access the live webcast of Gritstone Oncology's presentations through the Investors & Media section on their website, with replays available for 30 days after the events.

What is Gritstone Oncology's focus in cancer treatment?

Gritstone Oncology focuses on developing next-generation cancer immunotherapies using proprietary machine learning to identify tumor-specific neoantigens from patient biopsies.

What are the names of Gritstone Oncology's immunotherapy products?

Gritstone Oncology is developing two main immunotherapies: GRANITE, an individualized neoantigen-based therapy, and SLATE, a shared neoantigen-based therapy.

What technology does Gritstone Oncology use for developing cancer therapies?

Gritstone Oncology utilizes a machine learning-based platform, Gritstone EDGE, to predict tumor-specific neoantigens for developing personalized cancer treatments.